Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)

Following the publication of this article, the authors requested the following corrections: Page 2: The sentence “Three of the four patients with constitutional trisomy 21 achieved CR with MRD response, two completed study in remission and were still alive at last follow-up”. changed to “All four patients with constitutional trisomy 21 achieved CR with MRD response, two completed study in remission and were still alive at last follow-up”. Page 4: The sentence “Achievement of CR in three of four patients with constitutional trisomy 21 suggests that blinatumomab could be particularly useful to treat these fragile patients at risk of experiencing severe toxicities when exposed to aggressive chemotherapy.” changed to “Achievement of CR in all four patients with constitutional trisomy 21 suggests that blinatumomab could be particularly useful to treat these fragile patients at risk of experiencing severe toxicities when exposed to aggressive chemotherapy”. The authors confirm no change to the conclusions of the article.